Meeting
2018 Genitourinary Cancers Symposium
Real world outcomes of upfront docetaxel for hormone naïve metastatic prostate cancer in an ethnically diverse inner-city population.
Authors
Surabhi Pathak
John H. Stroger, Jr. Hospital of Cook County, Chicago, IL
Surabhi Pathak , Romy Jose Thekkekara , Ahmed T Ahmed , Udit Yadav , Michael Russell Mullane , Kumar Kunnal Batra , Thomas E. Lad , Sarah P Psutka
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, and Testicular Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 359)
DOI
10.1200/JCO.2018.36.6_suppl.359
Abstract #
359
Poster Bd #
E6
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
Patterns of response to androgen deprivation therapy in younger patients with locally advanced or metastatic prostate cancer.
First Author: Matthew Keating
Poster
2023 ASCO Annual Meeting
Open-label study of darolutamide plus androgen-deprivation therapy (ADT) vs ADT in metastatic hormone-sensitive prostate cancer using an external control arm (ARASEC).
First Author: Neal D. Shore
Poster
2023 ASCO Annual Meeting
The relationship between a priori defined prognostic risk groups and and overall survival (OS) in men with metastatic hormone sensitive prostate cancer (mHSPC).
First Author: Susan Halabi
Poster
2023 ASCO Genitourinary Cancers Symposium
A retrospective review of the benefits vs. safety implications of prednisolone during docetaxel chemotherapy alongside androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC).
First Author: Molly Jameson